Galeterone
Encyclopedia
Galeterone also known as TOK-001 or VN/124-1 is drug that being developed by Tokai Pharmaceuticals, Inc. for the treatment of prostate cancer
. It is both an androgen receptor
antagonist and CYP17A1 inhibitor. It is currently being tested in early phase I/II clinical trials for castration resistant prostate cancer.
Prostate cancer
Prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostate cancers. The cancer cells may metastasize from the prostate to other parts of the body, particularly...
. It is both an androgen receptor
Androgen receptor
The androgen receptor , also known as NR3C4 , is a type of nuclear receptor that is activated by binding of either of the androgenic hormones testosterone or dihydrotestosterone in the cytoplasm and then translocating into the nucleus...
antagonist and CYP17A1 inhibitor. It is currently being tested in early phase I/II clinical trials for castration resistant prostate cancer.